Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) Trial: Rationale and design

American Heart Journal

Volumn 155, Issue 2, 2008, Pages 224-230

  Myles, Paul S ^a,b,c   Smith, Julian ^b,d   Knight, John ^e   Cooper, D James ^a,b   Silbert, Brendan ^f,g   McNeil, John ^b   Esmore, Donald S ^a,b   Buxton, Brian ^h   Krum, Henry ^b,c   Forbes, Andrew ^b   Tonkin, Andrew ^b,c  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c Australian National Health and Medical Research Council Centre for Clinical Research Excellence in T   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

^e FLINDERS MEDICAL CENTRE   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; TRANEXAMIC ACID;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY SURGERY; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OFF PUMP CORONARY SURGERY; OUTCOME ASSESSMENT; PATIENT SELECTION; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE;

ANTIFIBRINOLYTIC AGENTS; ASPIRIN; CORONARY ARTERY BYPASS; EPIDEMIOLOGIC RESEARCH DESIGN; FIBRINOLYTIC AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; TRANEXAMIC ACID;

EID: 38149070140     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.10.003     Document Type: Article

References (45)

1. Nalysnyk L., Fahrbach K., Reynolds M.W., et al. Adverse events in coronary artery bypass graft (CABG) trials: a systematic review and analysis. Heart 89 (2003) 767-772
2. Tu J.V., Jaglal S.B., and Naylor C.D. Multicenter validation of a risk index for mortality, intensive care stay, and overall hospital length of stay after cardiac surgery. Circulation 91 (1995) 677-684
3. Shroyer A.L., Coombs L.P., Peterson E.D., et al. The Society of Thoracic Surgeons: 30-day operative mortality and morbidity risk models. Ann Thorac Surg 75 (2003) 1856-1864
4. Taylor G.J., Mikell F.L., Moses H.W., et al. Determinants of hospital charges for coronary artery bypass surgery. The economic consequences of postoperative complications. Am J Cardiol 65 (1990) 309-313
5. Despotis G.J., Levine V., Filos K.S., et al. Factors associated with postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 82 (1996) 13-23
6. Grayson A.D., Jackson M., and Desmond M.J. Monitoring blood transfusion in patients undergoing coronary artery bypass grafting: an audit methodology. Vox Sang 85 (2003) 96-101
7. Chelemer S., Prato B.S., Cox Jr. P.M., et al. Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgery. Ann Thorac Surg 73 (2002) 138-142
8. Bélisle S., and Hardy J.F. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Ann Thorac Surg 62 (1996) 1908-1917
9. Brown J.R., Birkmeyer N.J., and O'Connor G.T. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115 (2007) 2801-2813
10. Levi M., Cromheecke M.E., de Jonge E., et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 354 (1999) 1940-1947
11. Alderman E.L., Levy J.H., Rich J.B., et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 116 (1998) 716-730
12. Ferraris V.A., Ferraris S.P., Saha S.P., et al. Peri-operative blood transfusion & blood conservation in cardiac surgery. www.sts.org/documents/pdf/BloodConservationGuidelines02.08.2007.pdf [accessed April 20, 2007]
13. Henry D.A., Moxey A.J., Carless P.A., et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 1 (2001) CD001886
14. Mangano D.T., Tudor I.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
15. Mangano D.T., Miao Y., Vuylsteke A., et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 297 (2007) 471-479
16. Karkouti K., Beattie W.S., Dattilo K.M., et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 46 (2006) 327-338
17. Dentz M.E., Slaughter T.F., and Mark J.B. Early thrombus formation on heparin-bonded pulmonary artery catheters in patients receiving epsilon aminocaproic acid. Anesthesiology 82 (1995) 583-586
18. Kluger R., Olive D.J., and Stewart A.B. Epsilon-aminocaproic acid in coronary artery bypass graft surgery: preincision or postheparin?. Anesthesiology 99 (2003) 1263-1269
19. Risch A., Dorscheid E., Stein G., et al. The effect of aprotinin and tranexamic acid on fibrinolysis and thrombin generation during cardiopulmonary bypass. Anaesthesist 49 (2000) 279-285
20. Sedrakyan A., Atkins D., and Treasure T. The risk of aprotinin: a conflict of evidence. Lancet 367 (2006) 1376-1377
21. Body S., and Mazer C.D. Pro: aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery. Anesth Analg 103 (2006) 1354-1359
22. Royston D., van Haaften N., and De Vooght P. Aprotinin; friend or foe? A review of recent medical literature. Eur J Anaesthesiol 24 (2007) 6-14
23. Sackett D.L. Bias in analytic research. J Chronic Dis 32 (1979) 51-63
24. MacMahon S., and Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity. II: observational studies. Lancet 357 (2001) 455-462
25. Datta M. You cannot exclude the explanation you have not considered. Lancet 342 (1993) 345-347
26. Day J.R., Landis R.C., and Taylor K.M. Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction. Semin Cardiothorac Vasc Anesth 10 (2006) 132-142
27. Frumento R.J., O'Malley C.M., and Bennett-Guerrero E. Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens. Ann Thorac Surg 75 (2003) 479-483
28. Ferraris V.A., Ferraris S.P., Joseph O., et al. Aspirin and postoperative bleeding after coronary artery bypass grafting. Ann Surg 235 (2002) 820-827
29. Tuman K.J., McCarthy R.J., O'Connor C.J., et al. Aspirin does not increase allogeneic blood transfusion in reoperative coronary artery surgery. Anesth Analg 83 (1996) 1178-1184
30. Mangano D.T., and Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 347 (2002) 1309-1317
31. Srinivasan A.K., Grayson A.D., Pullan D.M., et al. Effect of preoperative aspirin use in off-pump coronary artery bypass operations. Ann Thorac Surg 76 (2003) 41-45
32. Goldman S., Copeland J., Moritz T., et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 77 (1988) 1324-1332
33. Goldman S., Copeland J., Moritz T., et al. Starting aspirin therapy after operation: effects on early graft patency. Circulation 84 (1991) 520-526
34. Gavaghan T., Gebski V., and Baron D.W. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. Circulation 83 (1991) 1526-1533
35. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 308 (1994) 159-168
36. Burger W., Chemnitius J.M., Kneissl G.D., et al. Low-dose aspirin for secondary prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis. J Intern Med 257 (2005) 399-414
37. Ferraris V.A., Ferraris S.P., Moliterno D.J., et al. The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary). Ann Thorac Surg 79 (2005) 1454-1461
38. Sadony V., Korber M., Albes G., et al. Cardiac troponin I plasma levels for diagnosis and quantitation of perioperative myocardial damage in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg 13 (1998) 57-65
39. Thielmann M., Massoudy P., Schmermund A., et al. Diagnostic discrimination between graft-related and non-graft-related perioperative myocardial infarction with cardiac troponin I after coronary artery bypass surgery. Eur Heart J 26 (2005) 2440-2447
40. Carrier M., Pellerin M., Perrault L.P., et al. Troponin levels in patients with myocardial infarction after coronary artery bypass grafting. Ann Thorac Surg 69 (2000) 435-440
41. Nussmeier N.A., Whelton A.A., Brown M.T., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
42. Roques F., Nashef S.A., Michel P., et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 15 (1999) 816-822
43. Tunis S., Stryer D.B., and Clancy C.M. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 290 (2003) 1624-1632
44. Dowd N.P., Karski J.M., Cheng D.C., et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 97 (2002) 390-399
45. Klein M., Keith P.R., Dauben H.P., et al. Aprotinin counterbalances an increased risk of perioperative hemorrhage in CABG patients pre-treated with aspirin. Eur J Cardiothorac Surg 14 (1998) 360-366